Clinical Trials Logo

Cervical Cancer Screening clinical trials

View clinical trials related to Cervical Cancer Screening.

Filter by:

NCT ID: NCT06229275 Not yet recruiting - Clinical trials for Cervical Cancer Screening

Study to Evaluate the Effectiveness of the Personal Pap Smear Device™ for Collection of Cervical Cells

Start date: February 2, 2024
Phase: Phase 3
Study type: Interventional

This purpose of this research study is to determine the effectiveness of the Personal Pap Smear TM Device to collect adequate cervical cell samples for cytology examination when compared with the Rover Cervex-Brush (Cervix-Examination Brush).

NCT ID: NCT06204133 Recruiting - Clinical trials for Artificial Intelligence

Model Study on Cervical Cancer Screening Strategies and Risk Prediction

Start date: November 1, 2023
Phase:
Study type: Observational

By collecting non-image medical data of women undergoing cervical screening in multiple centers in China, including age, HPV infection status, HPV infection type, TCT results, and colposcopy biopsy pathology results, a multi-source heterogeneous cervical lesion collaborative research big data platform was established. Based on artificial intelligence (AI) machine learning, cervical lesion screening features are refined, a multi-modal cervical cancer intelligent screening prediction and risk triage model is constructed, and its clinical application value is preliminarily explored.

NCT ID: NCT06178549 Recruiting - Clinical trials for Cervical Cancer Screening

Emergency Room HPV Self-Sampling Study (ACT NOW)

ACT NOW
Start date: November 15, 2023
Phase: N/A
Study type: Interventional

The goal of this study is to develop and evaluate an evidence-based public health intervention using HPV self-sampling approach in an opportunistic setting to increase cervical cancer screening among screening non-attendees, particularly those uninsured or underinsured, who use emergency services to access medical care. The proposed pilot study will examine the feasibility and efficacy of HPV self-sampling among women at a safety net hospital emergency room. Participant recruitment and self-sample will take place in the waiting rooms in the ER. All women sitting in the waiting room will serve as the source population for the study and will be approached and invited to participate in the study.

NCT ID: NCT05762757 Recruiting - Clinical trials for Cervical Cancer Screening

Patient-centered Educational Material to Improve Colposcopy Adherence

Start date: January 30, 2024
Phase: N/A
Study type: Interventional

The long-term goal is to develop, test, and disseminate a social needs navigator intervention that improves colposcopy adherence. Based on stakeholder feedback, this study addresses the need to include patient-centered educational material to the navigator program in order to improve patients' health literacy regarding cervical cancer prevention.

NCT ID: NCT05426642 Not yet recruiting - Clinical trials for Cervical Cancer Screening

The Effect of E-health Video Towards Enhancing Cervical Cancer Screening

Start date: March 2023
Phase: N/A
Study type: Interventional

The aim of this quasi-experimental study is to evaluate the women's motivation related to cervical cancer screening. The experiment group will receive the e-health video KaSEH and brochure as the intervention. Where as, the control group will receive brochure as the intervention. There is three phase of evaluation which are pre-intervention, intra-intervention and post-intervention. The evaluation will be assess using the self-administered questionnaire based on Protection Motivation Theory. The estimated duration of this quasi-experiment is six month.

NCT ID: NCT05414929 Active, not recruiting - HPV Infection Clinical Trials

Acceptability of HPV Self-sampling Among Canadian Women Aged 21 to 65

CUTE-IPS
Start date: April 4, 2022
Phase: N/A
Study type: Interventional

We propose a cross-sectional study to explore the acceptability and feasibility of HPV self-sampling among Quebec women. The study will invite eligible women to self-sample for HPV at home. The HPV risk factors of patients included in the study will be taken into consideration (vaccination, smoking, number of partners, date of last screening, etc.).

NCT ID: NCT05314907 Recruiting - Clinical trials for Cervical Cancer Screening

Acceptability of Self-sampling for Cervical Cancer Screening

Start date: November 28, 2018
Phase: N/A
Study type: Interventional

Main objectives: 1.1. To evaluate the use of self-sampling for HPV test in regular attendants of cervical cancer screening as a primary sample collection method. 1.2. To assess the impact on the acceptability of an educational intervention. 1.3 Confirm the concordance of HPV detection in the samples collected by the professional and in self-sampling. Project methodology: Randomized, parallel multicenter clinical trial in women aged 30-65 years regularly attending cervical cancer screening residents in the Autonomous Communities of Catalonia and the Canary Islands (Spain). The woman attends the routine screening visit where the health professional collects a sample from the cervical screening. She then offers her the study and if the woman accepts, she offers her the SS as a screening test. The modality of information and practice of the self-sampling is random: 1. Training group): Educational intervention with self-sampling practice: clinician-led explanation on how to proceed with self-sampling prior to collecting a self-sample at the clinic. 2. No prior trainning group): Same training without practicing self-sampling collection. Both groups has a standard of care cervical sample collection by a clinician. Women are asked to return a self-sampling specimen one month after the baseline visit together with an acceptability questionnaire on self-sampling use. Acceptability will be analyzed according to two definitions: - proportion of women who returned the self-sampling device, - proportion of women who report wanting to use self-sampling in future screens in the acceptability questionnaire. HPV agreement between collection methods will be calculated using Cohen's Kappa coefficient. Cost-effectiveness analisis will be done on public health system by a mathematical model of the cervical cancer natural history and HPV, adjusted for data in Spain. Self-sampling device uses in this trial is Evalyn Brush from Rovers and the HPV detection is COBAS 4800 from Roche.

NCT ID: NCT05286749 Completed - Clinical trials for Cervical Cancer Screening

Cervical Cancer Self-Collection for Southeast Asian Immigrant and Refugee Women

Start date: August 13, 2022
Phase: N/A
Study type: Interventional

The primary purpose of this study is to determine whether educational workshops paired with self-collected high-risk human papillomaviruses (hrHPV) screening will increase participation in cervical cancer screening among Southeast Asian Immigrant and Refugee populations in Wisconsin compared with offering clinician collected screening (total sample size: 250 participants). The investigators hypothesize that participation in cervical cancer screening will be higher among women in the intervention group as compared to the control group.

NCT ID: NCT05286034 Not yet recruiting - Cervical Cancer Clinical Trials

Using Artificial Intelligence-based ChatBot to Improve Women's Participation to Cervical Cancer Screening Programme

AppDate-You
Start date: June 1, 2024
Phase: N/A
Study type: Interventional

This project looks to improve the return rate of HPV self-sampling (HPVss) as well as the management of women HPVss positive.

NCT ID: NCT05256862 Recruiting - Clinical trials for Cervical Cancer Screening

Improving Cervical Cancer Screening in Women Living With HIV Attending Chronic Disease Clinics in Semi-rural Tanzania

Start date: July 27, 2021
Phase:
Study type: Observational

This study is to analyse the effect of a bundle of measures on the proportion of females being screened for cervical cancer in the Kilombero and Ulanga Antiretroviral Cohort (KIULARCO), comparing the time period before implementation (01/2017-01/2020) and after implementation (02/2020-06/2022). It is to assess the performance of two novel diagnostic tests (QuantiGene-molecular profiling histology (QG-MPH) and PT Monitor® immunoassay) and established tests (Seegene Anyplex™ II 28 HPV Test and Prevo-check®) as potential triage tests for the development of future clinical decision algorithms for CC screening.